SBIR Phase I: Corneal Tissue Restoration with Engineered Tissue

SBIR 第一阶段：用工程组织修复角膜组织

• 批准号: 2342532
• 负责人: Amelia Zellander
• 金额: $ 27.44万
• 依托单位: BIOLATTICE, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-12-01 至 2024-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2342532&HistoricalAwards=false
• 关键词: SBIR; Phase; Corneal; Tissue; Restoration

This Small Business Innovation Research (SBIR) Phase I project includes reduces the financial burden of cornea blindness and advances the medical device manufacturing industry in the US. Vision loss costs communities in lost wages and medical expenses. In 2018, the combined cost for blindness and MSVI (moderate and severe vision impairment) was $55.51 billion in North America. By providing a treatment for cornea blindness equivalent to s donor cornea, this innovation would help restore the vision of patients affected by corneal blindness, improve their ability to contribute to society, and lower the burden on their caretakers. In addition, by contributing to the general process of tissue engineering, the engineered cornea will help foster research in the field of alternatives to donor tissues, which will contribute to the well-being of individuals in society as a whole. The development of engineered cornea would also help advance the position of the US in the cornea replacement material field and more generally in the engineered tissue research field and could result in growth opportunities in the medical device manufacturing industry, therefore increasing US competitiveness.This Small Business Innovation Research (SBIR) Phase I project creates a novel acellular polymer membrane for use as a cornea substitute. The artificial cornea will differentiate itself from other artificial cornea options by offering a true alternative to donor cornea for full thickness cornea replacement (also known as penetrating keratoplasty). The artificial cornea will consist of a crosslinked polymer membrane that will provide biocompatibility with ocular tissues and suturability similar to a donor cornea. In addition, specific surface modifications will be added to the membrane to maintain its optical clarity, by preventing the adhesion of environmental and biological contaminants. These modifications will enable secure integration into the patient’s eye. The new materials will be aesthetically equivalent to existing donor cornea. By contrast to current artificial cornea options, the artificial cornea aims to provide a true replacement to donor cornea that can be used as a standard of care treatment for full thickness cornea replacement, without the risks generally associated with donor cornea tissue and without the need for refrigeration or complicated transport logistics.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目减少了角膜盲人的财务负担严重的视力障碍）在北美提供了55.1亿美元。通过为组织工程的一般过程做出贡献，工程角膜将在供体组织的替代领域构成拱形，这将有助于社会中的个人福祉。角膜替代物产物领域，更通常是英国组织场，并导致医疗设备制造业的竞争力。通过提供供体角膜的真正替代品（也称为穿透性角膜成形术）的选择。通过添加到可持续性的植物素质的粘附力，可以将其添加到可持续性的情况下。提供真正替代供体角膜，可以用作护理治疗标准的福NEA角膜角膜替换RNEA组织，并用于制冷或复杂的Trogistics。这奖反映了NSF'SF'SF'Sf'd，具有值得支持的Torough Torough评估利用基金会的知识分子和更广泛的影响审查标准。